RVMD — Revolution Medicines Income Statement
0.000.00%
Last trade - 00:00- $18.33bn
- $16.58bn
Annual income statement for Revolution Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 29.4 | 35.4 | 11.6 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 217 | 294 | 499 | 690 | 1,182 |
| Operating Profit | -188 | -258 | -487 | -690 | -1,182 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -187 | -249 | -440 | -601 | -1,131 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -187 | -249 | -436 | -600 | -1,131 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -187 | -249 | -436 | -600 | -1,131 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -187 | -249 | -436 | -600 | -1,131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.57 | -3.08 | -3.86 | -3.58 | -5.95 |